Invizius Company
Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. Invizius develops H-Guard, an advanced hemocompatible coating capable of preventing foreign body reactions in the blood at the source. Invizius aims to revolutionize dialysis and other extracorporeal treatments.
Industry:
Preventive Medicine
Technology:
Other
Funding Status:
Seed
Investment Stage:
N/A
Headquarters:
Edinburgh, Edinburgh, City of, United Kingdom
Employee Number:
Undisclosed
Number Of Exists:
N/A
Investor Type:
N/A
Founded Date:
2017